Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Next-generation sequencing has significantly advanced the understanding of tumor biology.
• Isocitrate dehydrogenase (IDH) mutations are early and prevalent in specific glioma subtypes, including astrocytomas and oligodendrogliomas.
• These mutations are also observed in certain myeloid malignancies and soft tissue tumors, but are infrequent in other cancers.

Purpose of the Study:

• To highlight the diagnostic and prognostic significance of IDH mutations in gliomas.
• To discuss the potential of IDH mutation status in refining glioma classification.
• To explore the emerging understanding of mutant IDH mechanisms and therapeutic implications.

Main Methods:

• Detection of IDH mutations through immunohistochemistry and standard sequencing techniques.
• Analysis of IDH mutation prevalence across various tumor types.
• Investigation into the biological mechanisms of mutant IDH, including epigenetic dysregulation and oxidative damage.

Main Results:

• IDH mutations are common and early events in astrocytomas, oligodendrogliomas, and oligoastrocytomas.
• IDH mutation status holds significant prognostic relevance for glioma patients.
• Understanding mutant IDH mechanisms is rapidly progressing, linking to proneoplastic processes.

Conclusions:

• IDH mutation detection is valuable for routine pathology practice, aiding diagnosis.
• IDH mutation status is poised to be integrated into future WHO glioma classifications.
• Assessing IDH mutation status in all gliomas is recommended due to its diagnostic, prognostic, and therapeutic implications.